Hanna, Michael G <br/><br/>
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.  [electronic resource] 

 -  The Lancet. Neurology  09 2019 
 - 834-844 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-4465 
<br/><br/><label>Standard No.: </label>10.1016/S1474-4422(19)30200-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Myositis, Inclusion Body--drug therapy<br/>Treatment Outcome